Ensysce Biosciences Inc
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Ensysce Biosciences' stock, anticipating a significant rise in value.
Financial Health
Ensysce Biosciences is generating modest revenue, cash flow, and has a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ENSC
Beyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage potential
The company’s R&D progress and partnerships can be catalysts for value, though outcomes are uncertain and timelines may be long.
High volatility risk
With a small market cap and limited liquidity, share prices can swing widely; suitable only for risk-tolerant investors.
Regulatory milestones matter
Clinical and regulatory updates can be decisive for valuation; keep an eye on filings and press releases for news, while noting possible delays.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
